Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mitsuharu, Hashimura"'
Autor:
Soichiro, Nakako, Hiroshi, Shiragami, Mitsuharu, Hashimura, Hiroyoshi, Ichihara, Atsuko, Mugitani
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 62(3)
A 67-year-old man with multiple myeloma had been treated with carfilzomib, lenalidomide, and dexamethasone (KRd) therapy. During the second course, he developed dyspnea, which gradually worsened. After admission, gastrointestinal losses of magnesium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1bf24a0459059e38da081c65fcb872fb
https://pubmed.ncbi.nlm.nih.gov/33828013
https://pubmed.ncbi.nlm.nih.gov/33828013
Autor:
Hoyuri, Fuseya, Takafumi, Nakao, Mitsuharu, Hashimura, Mirei, Horiuchi, Yoshiki, Hayashi, Kiyoyuki, Hagihara, Hiroshi, Kanashima, Takahiro, Okuno, Hiroko, Fukushima, Takeshi, Inoue, Takao, Manabe, Takahisa, Yamane
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 58(7)
Lymphomatosis cerebri (LC) is a rare variant of primary central nervous system lymphoma, and it is characterized by diffuse cerebral infiltration of malignant lymphoma cells without evidence of a mass lesion. Herein, we report a patient with systemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::00a40b090f1ffe31134a3d0597acb759
https://pubmed.ncbi.nlm.nih.gov/28781271
https://pubmed.ncbi.nlm.nih.gov/28781271
Publikováno v:
Blood. 126:1688-1688
Introduction: Clinically we categorized myelodysplastic syndromes with progressing stages or with disease-related symptoms (fever, edema, pneumonia like shadow, etc) as an aggressive type MDS (aMDS). We hypothesized that these aggressive phases were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09cbdaacb6026926d90815109c8e746d
https://doi.org/10.1182/blood.v126.23.1688.1688
https://doi.org/10.1182/blood.v126.23.1688.1688
Autor:
Manabu Hirai, Erina Sakamoto, Masayuki Hino, Mizuki Aimoto, Mitsuharu Hashimura, Atsushi Inoue, Hirohisa Nakamae
Publikováno v:
Blood. 124:3260-3260
Introduction: Conversion to overt leukemia is the final, progressive and most aggressive stage in myelodysplastic syndromes (MDS). Azacitidine (AZA) is a promising agent for improving prognosis in higher-risk MDS, but inadequate as a single agent for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51bba9ffc80e7527fad7fe5f2c0e3aa2
https://doi.org/10.1182/blood.v124.21.3260.3260
https://doi.org/10.1182/blood.v124.21.3260.3260
Autor:
Atsushi Inoue, Takahiko Nakane, Erina Sakamoto, Masayuki Hino, Mitsuharu Hashimura, Mizuki Aimoto, Manabu Hirai, Hirohisa Nakamae
Publikováno v:
Blood. 122:1536-1536
Introduction Azacitidine (AZA) is a promising agent for higher risk myelodysplastic syndrome (MDS), but it does not prevent disease progression as a single agent in most cases of AML. MDS is a heterogeneous disease not only pathologically but also cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac58af5b114c09505118a3a9d65881be
https://doi.org/10.1182/blood.v122.21.1536.1536
https://doi.org/10.1182/blood.v122.21.1536.1536
Autor:
Manabu Hirai, Ryousuke Yamamura, Atsushi Inoue, Masayuki Hino, Yoshiki Terada, Hiroyoshi Ichihara, Erina Sakamoto, Hirohisa Nakamae, Mitsuharu Hashimura
Publikováno v:
Blood. 120:1187-1187
Abstract 1187 It has been shown that serum ferritin (SF) levels are associated with mortality in transfusion-dependent patients with MDS. Optimal dosing with deferasirox has been shown to decrease SF level even in transfusion-dependent patients and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4a00fac85126df1fb66f004ebfafd8a
https://doi.org/10.1182/blood.v120.21.1187.1187
https://doi.org/10.1182/blood.v120.21.1187.1187